Two new reflection papers to help shape relevant AMR Pull incentives

As EU trilogue negotiations on the pharmaceutical package are fast approaching, the BEAM Alliance calls for urgent action to address the collapse of antimicrobial R&D in Europe.

Today, we publish 2 reflection papers on one of the most challenging areas still within the revision of the General Pharmaceutical Legislation (GPL) – the incentives to support antimicrobial resistance (AMR) innovation.

The first paper makes the case for sufficient, predictable, and rapidly implementable incentives, and explains why the Transferable Exclusivity Extension (TEE) voucher remains the most viable tool on the table.

While no incentive is perfect, the TEE voucher offers a pragmatic path forward—and with key adjustments, it can form the backbone of a strong European contribution to global AMR efforts.

We also propose a two-stage model that combines the TEE with a top-up guarantee, ensuring the EU meets its fair share while maintaining alignment with public health goals.

Read the full paper here

The second paper outlines why rigid scientific criteria in the proposed GPL risk undermining innovation, particularly as antibiotics are usually developed through non-inferiority trials.

Instead, we propose a flexible, expert-led approach:

• Let scientific bodies like the EMA define eligibility, not legislative text;
• Use a stepwise, performance-based framework, including an early-stage eligibility status;
• Focus on clinical utility and public health value, not just novelty.

Read the full paper here

This is essential to ensure incentives are targeted, effective, and future-proof in the fight against AMR.